Natural Product (NP) Details
| General Information of the NP (ID: NP6132) | |||||
|---|---|---|---|---|---|
| Name |
Betulin
|
||||
| Synonyms |
Betulin; 473-98-3; Betulinol; Betuline; Trochol; Betulol; Lup-20(29)-ene-3beta,28-diol; Lup-20(29)-ene-3b,28-diol; UNII-6W70HN7X7O; NSC 4644; 6W70HN7X7O; CHEBI:3086; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; Betulinic alcohol; NSC-4644; MFCD00016802; Lup-20(30)-ene-3beta,28-diol; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosan-17-ol; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; SR-05000002167; EINECS 207-475-5; NSC4644; AI3-62999; NSC692218; Lup-20(29)-ene-3,28-diol, (3beta)-; (3beta)-lup-20(29)-ene-3,28-diol; Betulin, 23; Betulin, >=98%; Prestwick3_000990; Betulinol (obsol pound(c); Betulin, analytical standard; BSPBio_001059; ARONIS24303; CHEMBL23236; SCHEMBL131739; BPBio1_001165; MEGxp0_001726; ACon1_000091; BDBM23207; DTXSID101019934; HMS2098E21; EX-A3354; HY-N0083; ZINC3978650; s4754; SBB080743; Lup-20(29)-ene-3 ,28-diol; AKOS005267212; ACN-035289; CCG-208619; CS-6156; GS-3254; LMPR0106140005; NSC-692218; NCGC00168803-01; NCGC00168803-02; NCGC00168803-04; AB00513988; B0803; N1290; V0184; (3.beta.)-Lup-20(29)-ene-3,28-diol; C08618; Lup-20(29)-ene-3,28-diol, (3-beta)-; S-1793; 473B983; Q419726; Q-100501; SR-05000002167-2; SR-05000002167-3; BRD-K64874225-001-01-3; NCGC00168803-04_C30H50O2_Lup-20(29)-ene-3,28-diol, (3beta)-; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0(2),(1)?.0?,?.0(1)?,(1)?]henicosan-17-ol; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3 a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; (5S,17S,1R,2R,8R,9R,10R,13R,14R,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethy l-8-(1-methylvinyl)pentacyclo[11.8.0.0<2,10>.0<5,9>.0<14,19>]henicosan-17-ol
Click to Show/Hide
|
||||
| Species Origin | Betula pendula ... | Click to Show/Hide | |||
| Betula pendula | |||||
| Disease | Acute lymphoblastic leukemia [ICD-11: 2B33] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.04
MDCK Permeability
-4.907
PAMPA
-
HIA
- - -
Distribution
VDss
-0.007
PPB
93.2%
BBB
+++
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
+++
CYP2C9 inhibitor
- -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
+
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
-
Excretion
CLplasma
9.901
T1/2
0.722
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
+
Respiratory
+++
Human Hepatotoxicity
+
Ototoxicity
-
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
- -
Hematotoxicity
+
Genotoxicity
+
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C30H50O2
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO
|
||||
| InChI |
1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1
|
||||
| InChIKey |
FVWJYYTZTCVBKE-ROUWMTJPSA-N
|
||||
| CAS Number |
CAS 473-98-3
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | SREBF1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| MHCC97-L | CVCL_4973 | Adult hepatocellular carcinoma | Homo sapiens | |||
| MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | To establish the animal model, HCC cells were injected subcutaneously into nude mice. | |||||
| Experimental
Result(s) |
SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. | |||||
| Acyclovir | Virus infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Vero | CVCL_0059 | Healthy | Chlorocebus sabaeus | ||
| Experimental
Result(s) |
Strong and moderate synergistic antiviral effects were observed for betulin and ACV against HSV-1 when the concentrations of ACV and betulin were higher than 0.068 and 0.4 microg/ml, respectively. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Myophosphorylase (PYGM) | Molecule Info | [4] | |